Company: PFSA
Filing Date: 2025-10-09
Form Type: S-1
Source: 0001213900-25-097860
Chunk: 317

Company: Profusa, Inc.
Filing Date: 2025-10-09
Form: S-1
Chunk 317
---
 Convertible notes payable(1)     |     |                  | 42,430,263 |    |     |      | 25,721,548 |    |
| Convertible loans                |     |                  |          — | -2 |     |      |          — | -2 |
| Options to purchase common stock |     |                  |  4,520,250 |    |     |      |  2,972,055 |    |
| Total                            |     |                  | 64,814,447 |    |     |      | 46,557,537 |    |

| (1) | The conversion of the Convertible Notes and Senior Notes to common stock is dependent on the price of                                        
 SPAC transaction or other equity offering and the completion date of such offerings. These factors are not estimable, therefore, the number  
 of common stock is not determinable.                                                                                                         |
| (2) | The Tasly Convertible Notes issued between June and August 2023 and completed in February 2024                                               
 are convertible upon occurrence of various conversion scenarios. Therefore, the number of common stock shares issuable upon their conversion 
 is not currently estimable.                                                                                                                  |

F-50 PROFUSA, INC. AND SUBSIDIARY
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED) Note 12 — Government Grant Revenue Government grant revenue consists of amounts we earn under grants from two government agencies: NIH and DARPA. These grants are provided either in the form of expense reimbursement (expense reimbursement grants) or as on a fixed fee basis (fixed fee grants). Under the expense reimbursement grants the government agencies reimburse us for a portion of our expenses (allowable expenses) that have been incurred in a given period on the basis of reports that we provide to these agencies. Fixed fee grants are awarded for specific research and development programs undertaken by us. Under these grants we receive milestone payments from the government agencies upon our submission and approval by the government of agreed upon deliverables, consisting primarily of the documented results of the specific research and development programs.

Note 13 — Segments

|                                                                                 |     | Three Months Ended 
 June 30,           |   2025 |   |     |   |   2024 |   |
|:--------------------------------------------------------------------------------|:----|:-------------------|-------:|:--|:----|:--|-------:|:--|
| Government grant revenue                                                        |     |